{"id":227026,"date":"2025-12-13T01:18:19","date_gmt":"2025-12-13T07:18:19","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/12\/ank3-as-a-novel-genetic-biomarker-for-liafensine-in-treatment-resistant-depression-the-enlighten-randomized-clinical-trial"},"modified":"2025-12-13T01:18:19","modified_gmt":"2025-12-13T07:18:19","slug":"ank3-as-a-novel-genetic-biomarker-for-liafensine-in-treatment-resistant-depression-the-enlighten-randomized-clinical-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/12\/ank3-as-a-novel-genetic-biomarker-for-liafensine-in-treatment-resistant-depression-the-enlighten-randomized-clinical-trial","title":{"rendered":"ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression: The ENLIGHTEN Randomized Clinical Trial"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/ank3-as-a-novel-genetic-biomarker-for-liafensine-in-treatment-resistant-depression-the-enlighten-randomized-clinical-trial2.png\"><\/a><\/p>\n<p>Liafensine was efficacious and well tolerated in ANK3-positive patients with treatment-resistant depression, with clinically meaningful and statistically significant improvements over placebo, highlighting ANK3 as a predictive genetic biomarker for liafensine.<\/p>\n<hr>\n<p>Question Does the newly discovered ANK3 pharmacogenomic biomarker predict the response of patients with treatment-resistant depression (TRD) to liafensine, a triple reuptake inhibitor, despite failure in a non\u2013biomarker-selected TRD patient population in prior phase 2b trials?<\/p>\n<p><strong>Findings<\/strong> In this randomized clinical trial including 189 ANK3-positive patients with TRD, liafensine demonstrated a 4.4-point Montgomery-\u00c5sberg Depression Rating Scale improvement over placebo, a clinically meaningful and statistically significant difference.<\/p>\n<p><strong>Meaning<\/strong> This represents a first successful genetic biomarker-guided clinical trial in psychiatry, advancing a new treatment for TRD and providing a new path for developing precision medicines in the field.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Liafensine was efficacious and well tolerated in ANK3-positive patients with treatment-resistant depression, with clinically meaningful and statistically significant improvements over placebo, highlighting ANK3 as a predictive genetic biomarker for liafensine. Question Does the newly discovered ANK3 pharmacogenomic biomarker predict the response of patients with treatment-resistant depression (TRD) to liafensine, a triple reuptake inhibitor, despite failure [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412,47],"tags":[],"class_list":["post-227026","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/227026","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=227026"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/227026\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=227026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=227026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=227026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}